Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1757-1762

  Gauthier, Josée ^a   Bourne, Eric J ^a   Lutz, Michael W ^a   Crowther, Lynn M ^a   Dienstag, Jules L ^b   Brown, Nathaniel A ^a   Condreay, Lynn D ^a  

^a GLAXOSMITHKLINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MULTICENTER STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA; VIRUS TITRATION;

ANTIVIRAL AGENTS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE INHIBITORS; VARIATION (GENETICS); VIREMIA;

EID: 0032751727     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315147     Document Type: Article

References (16)

1. 1. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997;53:657-80.
2. 2. Severini A, Liu XY, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by ( )-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39:1430-5.
3. 3. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
4. 4. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-63.
5. 5. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
6. 6. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-3.
7. 7. Niesters HGM, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus ADME. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177:1382-5.
8. 8. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711-6.
9. 9. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-7.
10. 10. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-7.
11. 11. Dienstag JL, Schiff ER, Mitchell MC, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30:1082-7.
12. 12. Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of anti-hepatitis B compound selectivity by virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993; 37:441-7.
13. 13. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for the detection of variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:3338-47.
14. 14. Aspinall S, Steele AD, Peenze I, Mphahlele MJ. Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction. J Viral Hepat 1995; 2:107-11.
15. 15. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-61.
16. 16. Kaneko S, Miller RH, Fienstone SM. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 1989; 86:312-6.